Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFalpha Monoclonal Antibody, Administered Intravenously, in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Next Previous
X
Search
Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFalpha Monoclonal Antibody, Administered Intravenously, in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 May 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Golimumab (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms GO-FURTHER
  • Sponsors Centocor

    • Most Recent Events

    • 21 Mar 2022 Results of pooled analysis assessing safety of three studies (NCT00973479, NCT02181673 & NCT02186873) published in the Arthritis Research and Therapy.
    • 16 Feb 2022 Results of population pharmacokinetic and exposure-response model simulations assessing exposure and efficacy for maintenance doses of intravenous Golimumab published in the Clinical Therapeutics
    • 17 Sep 2021 Results of pharmacokinetic (PK) and exposure-response (E-R) modeling assessing whether shortening the IV dosing interval from Q8W to Q6W could reduce disruptions in symptom relief for some RA patients by using data from the Phase 3 GO-FURTHER study, presented at the 2021 American College of Clinical Pharmacology Annual Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top